SiBone (NASDAQ:SIBN) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Posted by Francis Steltz on Nov 2nd, 2026

SiBone (NASDAQ:SIBN – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05, FiscalAI reports. The firm had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%.

Here are the key takeaways from SiBone’s conference call:

Third-quarter revenue rose 14.5% to $55.7 million, while U.S. procedure volume increased 19.5% and active physicians grew 16% to approximately 1,770. Management cited broad-based demand across surgeons, interventional spine physicians, and trauma procedures.
The early alpha launch of iFuse Granite Onyx is generating demand ahead of the comparable Granite launch, including adoption by existing Granite users and new physicians. Onyx expands the company’s estimated addressable market to more than 650,000 procedures and approximately $5 billion.
New spinal-fusion DRGs became effective October 1 and may increase hospital reimbursement by up to $50,000 for qualifying cases, supporting Granite adoption and potentially Onyx utilization. SI-BONE has also applied for an Onyx NTAP, which could take effect in October 2027 if approved.
Profitability and cash generation improved, with adjusted EBITDA up 32.4% to $3.0 million, a 5.5% margin, and year-to-date operating cash flow of $4.4 million. The company lowered its expected 2026 operating-expense growth to 10.5% from 12% while reaffirming full-year revenue guidance of $231 million to $233 million.
Average selling price declined because of a higher mix of lower-priced INTRA procedures in ASC and office settings and more two-implant Granite cases. Management expects modest gross-margin pressure in 2027 as it adds Onyx surgical capacity and launches additional products, although it continues to target long-term operating leverage.

SiBone Trading Down 4.8%

Shares of SiBone stock traded down $1.01 during trading on Monday, hitting $20.22. The stock had a trading volume of 1,371,299 shares, compared to its average volume of 616,959. SiBone has a 12 month low of $11.48 and a 12 month high of $22.95. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The firm’s fifty day simple moving average is $19.41 and its 200-day simple moving average is $16.44. The stock has a market cap of $896.74 million, a PE ratio of -59.47 and a beta of 0.66.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. UBS Group upped their price objective on SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. TD Cowen lifted their target price on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Truist Financial boosted their target price on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Finally, Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.50.

View Our Latest Stock Report on SIBN

Insider Activity at SiBone

In other SiBone news, insider Anshul Maheshwari sold 11,636 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $20.11, for a total value of $233,999.96. Following the completion of the sale, the insider owned 223,284 shares of the company’s stock, valued at $4,490,241.24. This trade represents a 4.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura Francis sold 51,884 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $19.46, for a total value of $1,009,662.64. Following the transaction, the chief executive officer owned 321,386 shares of the company’s stock, valued at $6,254,171.56. This trade represents a 13.90% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 204,968 shares of company stock worth $3,998,918. Insiders own 4.00% of the company’s stock.

About SiBone

(Get Free Report)

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.